Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a disease that may be curable with a stem cell transplant from a donor.
- People aged 25 years or younger.
- People whose blood cancer is in remission, based on the standards used by the Children's Hospital of Philadelphia (CHOP) transplant program (confirm with trial site for disease-specific details).
- People who have had organ function and infection status checked according to the transplant program's standard procedures.
- People whose parent or guardian has signed a consent form, or people aged 18 and older who are able to sign consent themselves.
- People of childbearing potential who have had a negative pregnancy test as required by the institution.
Who may not be able to join:
- People whose physical health or functioning is rated below 60 on a standard performance scale (confirm with trial site).
- People for whom no suitable donor is available to donate mobilised peripheral blood stem cells.
- People who have Hodgkin lymphoma, or a type of lymphoma that is neither Burkitt lymphoma nor lymphoblastic lymphoma.
- People who are planned to receive a medication called alemtuzumab as part of their pre-transplant treatment.
- People who have a fully matched sibling donor available (a 10 out of 10 HLA match).
- People who do not meet the transplant program's standards for disease status, organ function, or infection status.
Regarding the donor (the person donating stem cells):
- An unrelated donor must meet the National Marrow Donor Program's criteria for donation.
- A related donor must be willing and able to donate mobilised peripheral blood stem cells, and must be at least a half-match (haploidentical) with the patient.
- Donors must be willing to receive a medication called G-CSF to stimulate stem cell production, and to undergo stem cell collection.
- Donors must be willing to sign a consent form to take part in the study.
- Specific tissue-type (HLA) matching requirements apply to both related and unrelated donors (confirm with trial site for details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Timothy Olson, MD, PhD, Children's Hospital of Philadelphia
Phone: 215-590-2820
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate number of patients with acute graft vs host disease (aGVHD); Evaluate number of patients with chronic graft vs host disease (cGVHD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.